Applied Therapeutics Dirección
Dirección controles de criterios 1/4
We currently do not have sufficient information about the CEO.
Información clave
Shoshana Shendelman
Chief Executive Officer (CEO)
US$9.5m
Compensación total
| Porcentaje del salario del CEO | 6.6% |
| Permanencia del CEO | 8.8yrs |
| Participación del CEO | 4.0% |
| Permanencia media de la dirección | less than a year |
| Promedio de permanencia en la Junta Directiva | 7.8yrs |
Actualizaciones recientes de la dirección
Recent updates
Applied Therapeutics: FDA Stance Change For Advisory Panel Bodes Well For Review
Sep 18Applied Therapeutics: Pushing Towards FDA Approval
Sep 04We're Hopeful That Applied Therapeutics (NASDAQ:APLT) Will Use Its Cash Wisely
Aug 01
Applied Therapeutics: Navigating Challenges In ARI Development For Rare Diseases
May 28Applied Therapeutics: Speedy Regulatory Review Of Govorestat Might Be Possible
Feb 16Is Applied Therapeutics (NASDAQ:APLT) In A Good Position To Deliver On Growth Plans?
Feb 16Will Applied Therapeutics (NASDAQ:APLT) Spend Its Cash Wisely?
Nov 13We're A Little Worried About Applied Therapeutics' (NASDAQ:APLT) Cash Burn Rate
Aug 11We're A Little Worried About Applied Therapeutics' (NASDAQ:APLT) Cash Burn Rate
May 19Applied Therapeutics: Buying This Beaten-Down, Undervalued Rare Disease Company's Stock
Jan 19Is Applied Therapeutics (NASDAQ:APLT) Using Debt In A Risky Way?
Nov 11Here's Why We're Watching Applied Therapeutics' (NASDAQ:APLT) Cash Burn Situation
Aug 13Applied Therapeutics trades higher on FDA Fast Track designation for rare metabolic disorder
Jun 17Will Applied Therapeutics (NASDAQ:APLT) Spend Its Cash Wisely?
May 15Independent Director Stacy Kanter Just Bought 100% More Shares In Applied Therapeutics, Inc. (NASDAQ:APLT)
Feb 26How Much Of Applied Therapeutics, Inc. (NASDAQ:APLT) Do Insiders Own?
Feb 18Applied Therapeutics to resume galactosemia study for AT-007
Feb 02Applied Therapeutics, Inc. (NASDAQ:APLT) Insiders Have Been Selling
Nov 24
Applied Therapeutics EPS misses by $0.21
Nov 12Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$161m |
| Mar 31 2024 | n/a | n/a | -US$194m |
| Dec 31 2023 | US$9m | US$630k | -US$120m |
| Sep 30 2023 | n/a | n/a | -US$97m |
| Jun 30 2023 | n/a | n/a | -US$73m |
| Mar 31 2023 | n/a | n/a | -US$70m |
| Dec 31 2022 | US$3m | US$588k | -US$83m |
| Sep 30 2022 | n/a | n/a | -US$95m |
| Jun 30 2022 | n/a | n/a | -US$105m |
| Mar 31 2022 | n/a | n/a | -US$105m |
| Dec 31 2021 | US$2m | US$588k | -US$106m |
| Sep 30 2021 | n/a | n/a | -US$102m |
| Jun 30 2021 | n/a | n/a | -US$104m |
| Mar 31 2021 | n/a | n/a | -US$106m |
| Dec 31 2020 | US$5m | US$578k | -US$94m |
| Sep 30 2020 | n/a | n/a | -US$88m |
| Jun 30 2020 | n/a | n/a | -US$69m |
| Mar 31 2020 | n/a | n/a | -US$49m |
| Dec 31 2019 | US$12m | US$550k | -US$46m |
| Sep 30 2019 | n/a | n/a | -US$35m |
| Jun 30 2019 | n/a | n/a | -US$28m |
| Mar 31 2019 | n/a | n/a | -US$23m |
| Dec 31 2018 | US$1m | US$500k | -US$17m |
Compensación vs. Mercado: Shoshana's total compensation ($USD9.49M) is above average for companies of similar size in the US market ($USD3.24M).
Compensación vs. Ingresos: Shoshana's compensation has increased whilst the company is unprofitable.
CEO
Shoshana Shendelman (45 yo)
8.8yrs
Permanencia
US$9,493,213
Compensación
Dr. Shoshana Shendelman, PhD, has been Director of Applied Therapeutics Inc. since January 2016. Prior to founding Applied, she founded Clearpoint Strategy Group, a boutique life science consulting firm, w...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Chair of the Board of Directors | no data | US$9.49m | 3.96% $ 41.3m | |
| CFO, Principal Financial Officer & Independent Director | less than a year | US$675.15k | 0.079% $ 821.8k | |
| Chief Medical Officer | 6.3yrs | US$3.04m | 0.15% $ 1.5m | |
| COO & Chief Business Officer | less than a year | sin datos | sin datos | |
| Chief Accounting Officer | 1.4yrs | sin datos | sin datos | |
| Chief Commercial Officer | less than a year | sin datos | sin datos |
1.0yrs
Permanencia media
57.5yo
Promedio de edad
Equipo directivo experimentado: APLT's management team is not considered experienced ( 1 years average tenure), which suggests a new team.
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Chair of the Board of Directors | 8.8yrs | US$9.49m | 3.96% $ 41.3m | |
| CFO, Principal Financial Officer & Independent Director | 8.4yrs | US$675.15k | 0.079% $ 821.8k | |
| Independent Director | 7.8yrs | US$85.65k | 0.39% $ 4.1m | |
| Independent Director | 5.6yrs | US$92.53k | 0.017% $ 181.8k | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Lead Independent Director | 7.7yrs | US$88.78k | 0.053% $ 549.2k | |
| Independent Director | 5.5yrs | US$94.40k | 0.055% $ 572.7k | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Chairman of Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos |
7.8yrs
Permanencia media
68yo
Promedio de edad
Junta con experiencia: APLT's board of directors are considered experienced (7.8 years average tenure).